Related Experiment Videos
Activated T cells and cytokine-induced CD3+CD56+ killer cells
G D Schmidt-Wolf1, R S Negrin, I G Schmidt-Wolf
1Department of Medicine, Virchow Clinic of Humboldt University, Berlin, Germany.
Annals of Hematology
|February 1, 1997
Summary
Developing cancer immunotherapy faces challenges with cytotoxic cell availability. Lymphokine-activated killer (LAK) cells, tumor-infiltrating lymphocytes (TILs), and cytokine-induced killer (CIK) cells show promise for removing residual tumor cells.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Cancer immunotherapy research has focused on adoptive cell transfer over the last 20 years.
- A key challenge in developing effective adoptive immunotherapy is sourcing suitable cytotoxic effector cells.
Purpose of the Study:
- To explore the potential of various immune effector cells for cancer treatment.
- To identify suitable cell types for adoptive immunotherapy against residual cancer cells.
Main Methods:
- Review of existing research on adoptive immunotherapy strategies.
- Analysis of different types of immune effector cells, including LAK, TIL, and CIK cells.
Main Results:
- Lymphokine-activated killer (LAK) cells have been investigated for their anti-cancer properties.
- Tumor-infiltrating lymphocytes (TILs) represent another avenue of T cell-based cancer immunotherapy.
- Cytokine-induced killer (CIK) cells offer a distinct approach to generating cytotoxic immune cells for cancer therapy.
Conclusions:
- The availability of appropriate cytotoxic cells remains a critical factor for successful adoptive cancer immunotherapy.
- LAK cells, TILs, and CIK cells are identified as potential candidates for eliminating residual tumor cells in cancer patients.